Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Several other brokerages have also weighed in on TRVI. Morgan Stanley lifted their target price on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. B. Riley upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Stifel Nicolaus lifted their price objective on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. D. Boral Capital reissued a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Trading Down 0.3%

TRVI opened at $11.18 on Friday. The stock’s 50 day simple moving average is $12.19 and its 200-day simple moving average is $9.50. The stock has a market cap of $1.43 billion, a PE ratio of -30.22 and a beta of 0.91. Trevi Therapeutics has a 1 year low of $3.47 and a 1 year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. Equities analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in Trevi Therapeutics by 4.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock valued at $195,000 after acquiring an additional 911 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after acquiring an additional 1,300 shares in the last quarter. Persistent Asset Partners Ltd increased its position in shares of Trevi Therapeutics by 3.3% in the second quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company’s stock valued at $234,000 after acquiring an additional 1,384 shares during the last quarter. BIT Capital GmbH boosted its position in Trevi Therapeutics by 32.0% during the third quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock valued at $62,000 after purchasing an additional 1,633 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Trevi Therapeutics by 20.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company’s stock valued at $66,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.